PhaseBio Pharmaceuticals (NASDAQ:PHAS) Downgraded to "Market Perform" at Cowen
PhaseBio Pharmaceuticals (NASDAQ:PHAS) Downgraded to "Market Perform" at Cowen
Cowen lowered shares of PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) from an outperform rating to a market perform rating in a report published on Monday morning, The Fly reports.
據The Fly報道,考恩在週一上午發佈的一份報告中將PhaseBio製藥公司(納斯達克:PHAS-GET評級)的股票評級從表現優於大盤下調至市場表現評級。
Several other equities analysts have also issued reports on PHAS. Stifel Nicolaus lowered PhaseBio Pharmaceuticals from a buy rating to a hold rating and cut their target price for the company from $15.00 to $1.00 in a research note on Wednesday, September 28th. Needham & Company LLC lowered PhaseBio Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, September 28th. William Blair lowered PhaseBio Pharmaceuticals from an outperform rating to a market perform rating in a research note on Wednesday, September 28th. Finally, Cowen lowered PhaseBio Pharmaceuticals to a market perform rating in a research note on Monday. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, PhaseBio Pharmaceuticals currently has an average rating of Hold and a consensus price target of $4.50.
其他幾位股票分析師也發佈了關於PHA的報告。Stifel Nicolaus在9月28日週三的一份研究報告中將PhaseBio PharmPharmticals的評級從買入下調至持有,並將該公司的目標價從15.00美元下調至1.00美元。Needham&Company LLC在9月28日星期三的一份研究報告中將PhaseBio製藥公司的評級從買入下調為持有。威廉·布萊爾在9月28日星期三的一份研究報告中將PhaseBio製藥公司的評級從表現優於大盤下調至市場表現。最後,考恩在週一的一份研究報告中將PhaseBio製藥公司的市場表現評級下調至市場表現。根據MarketBeat的數據,五位分析師對該股的評級為持有,PhaseBio製藥公司目前的平均評級為持有,共識目標價為4.50美元。
PhaseBio Pharmaceuticals Trading Down 28.9 %
PhaseBio製藥公司股價下跌28.9%
Shares of PhaseBio Pharmaceuticals stock opened at $0.14 on Monday. The firm has a market cap of $7.02 million, a P/E ratio of -0.07 and a beta of 2.87. PhaseBio Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $4.08. The stock's fifty day moving average price is $0.73 and its 200-day moving average price is $0.89.
PhaseBio製藥公司的股票週一開盤報0.14美元。該公司的市值為702萬美元,市盈率為-0.07,貝塔係數為2.87。PhaseBio PharmPharmticals的12個月低點為0.12美元,12個月高位為4.08美元。該股的50日移動均線價格為0.73美元,200日移動均線價格為0.89美元。
Institutional Investors Weigh In On PhaseBio Pharmaceuticals
機構投資者看好PhaseBio製藥公司
Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth about $41,000. Blair William & Co. IL lifted its holdings in shares of PhaseBio Pharmaceuticals by 56.0% during the first quarter. Blair William & Co. IL now owns 35,696 shares of the company's stock worth $47,000 after purchasing an additional 12,810 shares during the period. Prudential Financial Inc. acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter worth about $26,000. Renaissance Technologies LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the first quarter worth about $118,000. Finally, Jane Street Group LLC acquired a new stake in shares of PhaseBio Pharmaceuticals during the second quarter worth about $68,000. Hedge funds and other institutional investors own 49.02% of the company's stock.
大型投資者最近調整了對該公司的持股。Virtu Financial LLC在第一季度購買了PhaseBio PharmPharmticals的新股份,價值約41,000美元。布萊爾·威廉公司第一季度增持的PhaseBio PharmPharmticals股票增加了56.0%。在此期間,布萊爾·威廉公司又購買了12,810股,目前持有35,696股該公司股票,價值47,000美元。保誠金融在第二季度收購了PhaseBio PharmPharmticals的新股份,價值約2.6萬美元。復興科技有限責任公司在第一季度收購了PhaseBio製藥公司價值約11.8萬美元的新股份。最後,簡街集團在第二季度收購了PhaseBio製藥公司價值約6.8萬美元的新股份。對衝基金和其他機構投資者持有該公司49.02%的股份。
PhaseBio Pharmaceuticals Company Profile
PhaseBio製藥公司簡介
(Get Rating)
(獲取評級)
PhaseBio Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension.
PhaseBio製藥公司是一家臨牀階段的生物製藥公司,致力於心血管疾病新療法的開發和商業化。該公司正在籌備中的藥物包括:用於抗血小板治療替卡格雷的新型逆轉藥bentracimab(PB2452),用於治療肺動脈高壓的每週一次的血管活性腸肽受體激動劑pemziviptadil(PB1046),以及用於治療頑固性高血壓的口服藥物PB6440。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on PhaseBio Pharmaceuticals (PHAS)
- Is Lithium Stock Albemarle A Buy Before Next Week's Q3 Report?
- Gassed Up: Can Cheniere Energy Keep Climbing?
- Can American Airlines Stock Maintain Altitude?
- New Name SLB's Legacy Business is Behind its Strong Results
- Insiders And Institutions Put A Bottom In Dave & Buster's
- 免費獲取StockNews.com關於PhaseBio製藥(PHAs)的研究報告
- 在下週的第三季度報告之前,鋰股Albemarle是買入嗎?
- 加油:Cheniere Energy還能繼續攀升嗎?
- 美國航空公司的股票能保持高度嗎?
- 新名稱SLB的遺產業務是其強勁業績的背後
- 內部人士和機構看好Dave&Buster‘s
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得PhaseBio製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PhaseBio製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。